Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | TPH1 | P17752 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104659 | 0.85 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL27864057 | 0.84 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL14967446 | 0.84 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL12674441 | 0.83 | SLC7A5 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL5025015 | 0.83 | SLC7A5 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL1070680 | 0.83 | SLC7A5 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL9396067 | 0.82 | SLC7A5 (0.88) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL2319690 | 0.82 | SLC7A5 (0.88) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2729020 | 0.82 | HIF1A (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL5025091 | 0.82 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8557781-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557781-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8399614-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399614-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8153758-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080187491-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | AMBRX, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317670-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | PTMS, DNPEP, ANPEP | SLC7A5 244/4885ALPI 3972/4885PKM 1184/4885 |
| US-20080118464-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | SLC7A5 336/4885ALPI 4695/4885PKM 921/4885 |
| US-20080187491-A1 | For diagnosis, genetic engineering; post-translation modification | PTMS, ANPEP, AADAT | SLC7A5 336/4885ALPI 4695/4885PKM 921/4885 |
| US-20080194459-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, ANPEP, PTMS | SLC7A5 193/4885ALPI 3828/4885PKM 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.